SYNJ2 is a novel and potential biomarker for the prediction and treatment of cancers: from lung squamous cell carcinoma to pan-cancer

• Main Authors: Wei Hou (Author), Guo-Sheng Li (Author), Li Gao (Author), Hui-Ping Lu (Author), Hua-Fu Zhou (Author), Jin-Liang Kong (Author), Gang Chen (Author), Shuang Xia (Author), Hong-Yu Wei (Author)
• Format: Book
• Published: BMC, 2022-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background The roles and clinical values of synaptojanin 2 (SYNJ2) in lung squamous cell carcinoma (LUSC) remain unclear. Methods A total of 2824 samples from multi-center were collected to identify the expression of SYNJ2 in LUSC by using Wilcoxon rank-sum test, t-test, and standardized me...